Literature DB >> 7743894

Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy.

S D Baker1, R M Wadkins, C F Stewart, W T Beck, M K Danks.   

Abstract

Fluorescence digital imaging microscopy (FDIM) has been used to perform a cell cycle analysis of both the amount and the distribution of nuclear DNA topoisomerase I in individual CEM human leukemia cells. Cells were stained by indirect immunofluorescence methods using a polyclonal antiserum generated with a 21-amino-acid peptide representing amino acids 219-239 of human topoisomerase I. Immunohistochemical staining was followed by staining with Hoechst dye 33342, allowing DNA content to be determined in each cell. Cell cycle analysis showed that nuclear topoisomerase I content doubled (2.2-fold increase) as the cells progressed from G1 to G2/M phases of the cell cycle. However, when normalized for nuclear size, topoisomerase I content per nuclear area remained almost constant (1.3-fold increase). For comparison, we measured the amount of proliferating cell nuclear antigen (PCNA), a protein whose expression fluctuates during the cell cycle. Nuclear PCNA content increased 2.7-fold from G1 to S phase, then declined in G2/M- phases, whereas PCNA content per nuclear area increased 1.7-fold from G1 to S phase. We also measured topoisomerase I content in leucine-deprived cells to determine if altered growth conditions affect topoisomerase I protein expression. Compared to CEM cells in logarithmic growth, leucine-deprived CEM cells had 1.8-fold less topoisomerase I content per nuclear area. Subnuclear distribution studies of proliferating CEM cells showed topoisomerase I to be localized predominantly in the nucleoli throughout the cell cycle. In contrast, leucine-deprived cells exhibited a perinuclear distribution of topoisomerase I. Our results show that FDIM is a useful technique in determining the cell cycle position and both the content and the distribution of topoisomerase I as well as other nuclear proteins in individual cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7743894     DOI: 10.1002/cyto.990190208

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  11 in total

1.  The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53.

Authors:  C Gobert; A Skladanowski; A K Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff.

Authors:  D Strumberg; A A Pilon; M Smith; R Hickey; L Malkas; Y Pommier
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

Review 3.  Human DNA topoisomerase I: relaxation, roles, and damage control.

Authors:  John B Leppard; James J Champoux
Journal:  Chromosoma       Date:  2005-04-14       Impact factor: 4.316

Review 4.  Repair of topoisomerase I-mediated DNA damage.

Authors:  Yves Pommier; Juana M Barcelo; V Ashutosh Rao; Olivier Sordet; Andrew G Jobson; Laurent Thibaut; Ze-Hong Miao; Jennifer A Seiler; Hongliang Zhang; Christophe Marchand; Keli Agama; John L Nitiss; Christophe Redon
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

Review 5.  Topoisomerase I interactive drugs in children with cancer.

Authors:  C F Stewart; W C Zamboni; W R Crom; A Gajjar; R L Heideman; W L Furman; W H Meyer; P J Houghton; C B Pratt
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 6.  DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?

Authors:  A K Larsen; C Gobert
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

7.  Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas.

Authors:  J A Holden; M P Rahn; C J Jolles; S V Vorobyev; I B Bronstein
Journal:  Mol Pathol       Date:  1997-10

8.  Topoisomerase I inhibitors and drug resistance.

Authors:  R E Parchment; A Pessina
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

9.  Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities.

Authors:  K N Meyer; E Kjeldsen; T Straub; B R Knudsen; I D Hickson; A Kikuchi; H Kreipe; F Boege
Journal:  J Cell Biol       Date:  1997-02-24       Impact factor: 10.539

10.  The effect of 3β, 6β, 16β-trihydroxylup-20(29)-ene lupane compound isolated from Combretum leprosum Mart. on peripheral blood mononuclear cells.

Authors:  Fabianne Lacouth-Silva; Caroline V Xavier; Sulamita da S Setúbal; Adriana S Pontes; Neriane M Nery; Onassis Boeri de Castro; Carla F C Fernandes; Eduardo R Honda; Fernando B Zanchi; Leonardo A Calderon; Rodrigo G Stábeli; Andreimar M Soares; Izaltina Silva-Jardim; Valdir A Facundo; Juliana P Zuliani
Journal:  BMC Complement Altern Med       Date:  2015-11-25       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.